Skip to main content

Advertisement

SpringerLink
Log in

Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to investigate the sustained intraocular pressure (IOP) elevation after repeated anti-VEGF intravitreal injections (IVI) in patients with diabetic macular edema (DME).

Methods

A retrospective study included 140 eyes without prior glaucoma, treated with at least three anti-VEGF injections for DME between 2012 and 2016. IOP elevation was defined by an increase above baseline IOP by ≥6 mmHg. Baseline IOP was defined as the mean of IOP values before treatment initiation. Three groups were differentiated: group 1 without IOP elevation, groups 2 and 3 with IOP elevation and IOP <21 mmHg (group 2) and ≥21 mmHg (group 3). Rate and several risk factors of IOP elevation were assessed and compared between the three groups.

Results

IOP elevation occurred in ten eyes (7.1%). IOP was <21 mmHg in six eyes and ≥21 mmHg in four eyes. Statistically significant associations were found between IOP elevation and the number of injections, and HbA1c level. Two patients required local hypotonic treatment.

Conclusions

In a real-life setting, we confirmed in eyes with center-involved DME without prior glaucoma or IOP elevation that repeated anti-VEGF IVI may increase the risk of sustained IOP elevation in about 7% of eyes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Romero-Aroca P (2011) Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes 2:98–104. https://doi.org/10.4239/wjd.v2.i6.98

    Article  PubMed  PubMed Central  Google Scholar 

  2. Klein R, Klein BE, Moss SE, Cruickshanks KJ (1995) The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102:7–16

    Article  CAS  PubMed  Google Scholar 

  3. Yau JWY, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564. https://doi.org/10.2337/dc11-1909

    Article  PubMed  PubMed Central  Google Scholar 

  4. Delcourt C, Massin P, Rosilio M (2009) Epidemiology of diabetic retinopathy: expected vs reported prevalence of cases in the French population. Diabetes Metab 35:431–438. https://doi.org/10.1016/j.diabet.2009.06.002

    Article  CAS  PubMed  Google Scholar 

  5. Wells JA, Glassman AR, Ayala AR et al (2016) Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351–1359. https://doi.org/10.1016/j.ophtha.2016.02.022

    Article  PubMed  PubMed Central  Google Scholar 

  6. Heier JS, Korobelnik J-F, Brown DM et al (2016) Intravitreal Aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123:2376–2385. https://doi.org/10.1016/j.ophtha.2016.07.032

    Article  PubMed  Google Scholar 

  7. Massin P, Bandello F, Garweg JG et al (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399–2405. https://doi.org/10.2337/dc10-0493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Brown DM, Nguyen QD, Marcus DM et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022. https://doi.org/10.1016/j.ophtha.2013.02.034

    Article  PubMed  Google Scholar 

  9. Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801. https://doi.org/10.1016/j.ophtha.2011.12.039

    Article  PubMed  Google Scholar 

  10. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–1203. https://doi.org/10.1056/NEJMoa1414264

    Article  Google Scholar 

  11. Boyer DS, Nguyen QD, Brown DM et al (2015) Outcomes with as-needed Ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology 122:2504–2513.e1. https://doi.org/10.1016/j.ophtha.2015.08.006

    Article  PubMed  Google Scholar 

  12. Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615–625. https://doi.org/10.1016/j.ophtha.2011.01.031

    Article  PubMed  Google Scholar 

  13. Qu-Knafo L, Fajnkuchen F, Sarda V et al (2016) French practice patterns in the management of diabetic macular edema. J Fr Ophtalmol 39:521–526. https://doi.org/10.1016/j.jfo.2016.02.005

    Article  CAS  PubMed  Google Scholar 

  14. Xu Y, Tan CS (2016) Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. https://doi.org/10.1007/s10792-016-0241-4

  15. van der Reis MI, La Heij EC, De Jong-Hesse Y et al (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina Phila Pa 31:1449–1469. https://doi.org/10.1097/IAE.0b013e3182278ab4

    Article  Google Scholar 

  16. Tolentino M (2011) Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56:95–113. https://doi.org/10.1016/j.survophthal.2010.08.006

    Article  PubMed  Google Scholar 

  17. Ladas ID, Karagiannis DA, Rouvas AA et al (2009) Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina Phila Pa 29:313–318. https://doi.org/10.1097/IAE.0b013e31819a5f98

    Article  Google Scholar 

  18. Baek SU, Park IW, Suh W (2016) Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol 35:310–314. https://doi.org/10.3109/15569527.2015.1124886

    Article  CAS  PubMed  Google Scholar 

  19. Nariani A, Williams B, Hariprasad SM (2016) Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure. Indian J Ophthalmol 64:643–647. https://doi.org/10.4103/0301-4738.194329

    Article  PubMed  PubMed Central  Google Scholar 

  20. Beato J, Pedrosa AC, Pinheiro-Costa J et al (2016) Long-term effect of anti-VEGF agents on intraocular pressure in age-related macular degeneration. Ophthalmic Res 56:30–34. https://doi.org/10.1159/000444395

    Article  CAS  PubMed  Google Scholar 

  21. Agard E, Elchehab H, Ract-Madoux G et al (2015) Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can J Ophthalmol J Can Ophtalmol 50:127–131. https://doi.org/10.1016/j.jcjo.2014.11.004

    Article  Google Scholar 

  22. Yannuzzi NA, Patel SN, Bhavsar KV et al (2014) Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 158:319–327.e2. https://doi.org/10.1016/j.ajo.2014.04.029

    Article  CAS  PubMed  Google Scholar 

  23. Kim YJ, Sung KR, Lee KS et al (2014) Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol 157:1266–1271.e1. https://doi.org/10.1016/j.ajo.2014.02.035

    Article  CAS  PubMed  Google Scholar 

  24. Bakri SJ, Moshfeghi DM, Francom S et al (2014) Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology 121:1102–1108. https://doi.org/10.1016/j.ophtha.2013.11.029

    Article  PubMed  Google Scholar 

  25. Yu AL, Seidensticker F, Schaumberger M et al (2014) Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab. Clin Ophthalmol Auckl NZ 8:743–747. https://doi.org/10.2147/OPTH.S58410

    Article  Google Scholar 

  26. Mathalone N, Arodi-Golan A, Sar S et al (2012) Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 250:1435–1440. https://doi.org/10.1007/s00417-012-1981-0

    Article  CAS  Google Scholar 

  27. Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111–1114. https://doi.org/10.1136/bjo.2010.180729

    Article  PubMed  Google Scholar 

  28. Song BJ, Aiello LP, Pasquale LR (2016) Presence and risk factors for glaucoma in patients with diabetes. Curr Diab Rep 16:124. https://doi.org/10.1007/s11892-016-0815-6

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bressler SB, Almukhtar T, Bhorade A et al (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589–597. https://doi.org/10.1001/jamaophthalmol.2015.186

    Article  PubMed  PubMed Central  Google Scholar 

  30. Zhou Y, Zhou M, Xia S et al (2016) Sustained elevation of intraocular pressure associated with Intravitreal Administration of Anti-Vascular Endothelial Growth Factor: a systematic review and meta-analysis. Sci Rep 6:39301. https://doi.org/10.1038/srep39301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kiddee W, Montriwet M (2015) Intraocular pressure changes in non-glaucomatous patients receiving Intravitreal anti-vascular endothelial growth factor agents. PLoS One 10:e0137833. https://doi.org/10.1371/journal.pone.0137833

    Article  PubMed  PubMed Central  Google Scholar 

  32. Hoang QV, Mendonca LS, Della Torre KE et al (2012) Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 119:321–326. https://doi.org/10.1016/j.ophtha.2011.08.011

    Article  PubMed  Google Scholar 

  33. Al-Abdullah AA, Nowilaty SR, Asghar N et al (2015) Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema. Retina Phila Pa 35:440–448. https://doi.org/10.1097/IAE.0000000000000371

    Article  CAS  Google Scholar 

  34. Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548. https://doi.org/10.1016/j.ophtha.2012.09.006

    Article  PubMed  Google Scholar 

  35. Bressler SB, Glassman AR, Almukhtar T et al (2016) Five-year outcomes of Ranibizumab with prompt or deferred laser versus laser or Triamcinolone plus deferred Ranibizumab for diabetic macular edema. Am J Ophthalmol 164:57–68. https://doi.org/10.1016/j.ajo.2015.12.025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Pasquale LR, Kang JH, Manson JE et al (2006) Prospective study of type 2 diabetes mellitus and risk of primary open-angle glaucoma in women. Ophthalmology 113:1081–1086. https://doi.org/10.1016/j.ophtha.2006.01.066

    Article  PubMed  Google Scholar 

  37. Zhao D, Cho J, Kim MH et al (2015) Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology 122:72–78. https://doi.org/10.1016/j.ophtha.2014.07.051

    Article  PubMed  Google Scholar 

  38. Chopra V, Varma R, Francis BA et al (2008) Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino eye study. Ophthalmology 115:227–232.e1. https://doi.org/10.1016/j.ophtha.2007.04.049

    Article  PubMed  Google Scholar 

  39. de Voogd S, Ikram MK, Wolfs RCW et al (2006) Is diabetes mellitus a risk factor for open-angle glaucoma? The Rotterdam study. Ophthalmology 113:1827–1831. https://doi.org/10.1016/j.ophtha.2006.03.063

    Article  PubMed  Google Scholar 

  40. David R, Zangwill L, Briscoe D et al (1992) Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br J Ophthalmol 76:280–283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Syam PP, Mavrikakis I, Liu C (2005) Importance of early morning intraocular pressure recording for measurement of diurnal variation of intraocular pressure. Br J Ophthalmol 89:926–927. https://doi.org/10.1136/bjo.2004.052787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kahook MY, Ammar DA (2010) In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 19:437–441. https://doi.org/10.1097/IJG.0b013e3181ca74de

    Article  PubMed  Google Scholar 

  43. Liu L, Ammar DA, Ross LA et al (2011) Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 52:1023–1034. https://doi.org/10.1167/iovs.10-6431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ricca AM, Morshedi RG, Wirostko BM (2015) High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther 31:2–10. https://doi.org/10.1089/jop.2014.0062

    Article  CAS  Google Scholar 

Download references

Acknowledgements

AVOPH, the Association for Research in Vision and Ophthalmology, Ophthalmology department, Avicenne hospital, 125 rue de Stalingrad, 93000, Bobigny, supported this work.

Funding

No funding was received for this research.

Author information

Authors and Affiliations

  1. Ophthalmology Department, Avicenne Hospital, APHP, DHU Vision and Handicaps, Paris 13 University, 125 rue de Stalingrad, 93000, Bobigny, France

    S. Vo Kim, F. Fajnkuchen, V. Sarda, L. Qu-Knafo, B. Bodaghi & A. Giocanti-Aurégan

  2. Centre d’imagerie et de Laser, 11 rue Anoine Bourdelle, Paris, France

    F. Fajnkuchen

  3. Ophthalmology Department, Pitié-Salpétrière Hospital, APHP, DHU Vision and Handicaps, Paris 6 University, Paris, France

    B. Bodaghi

Authors
  1. S. Vo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Fajnkuchen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Sarda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Qu-Knafo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Bodaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Giocanti-Aurégan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Giocanti-Aurégan.

Ethics declarations

Conflict of interest

Vo Kim S, Sarda V, Qu-Knafo L, Bodaghi B have nothing to disclose. Fajnkuchen F, and Giocanti-Aurégan A, received fees from Allergan, Alimera, Bayer and Novartis outside of the submitted work.

Ethical approval

For this type of study formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vo Kim, S., Fajnkuchen, F., Sarda, V. et al. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting. Graefes Arch Clin Exp Ophthalmol 255, 2165–2171 (2017). https://doi.org/10.1007/s00417-017-3782-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-017-3782-y

Keywords

Search

Navigation